clinical trial · NCT01148849
Safety Study of MGAH22 in HER2-positive Carcinomas
MacroGenics·phase1·completed·n = 66
Breast CancerGastric Cancermargetuximab
brief summary
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.
started
Jul 1, 2010
primary completion
Jun 14, 2022
completion
Jun 14, 2022
last updated
Feb 26, 2025
official title
A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol